Kiniksa: Rises as COVID-19 drug succeeds mid-stage study

Kiniksa Pharmaceuticals International

12/04/2021 13:43

** Drug developer's shares  KNSA.O  rise 3.9% to $18.39
premarket after co says a portion of a mid-stage study testing
mavrilimumab met its main goal 
    ** Mavrilimumab is co's investigational fully-human
monoclonal antibody to treat patients with severe pneumonia and
hyperinflammation caused by COVID-19  urn:newsml:reuters.com:*:nGNX6vzWY8
    ** Says study met goal of proportion of patients alive and
free of mechanical ventilation at day 29 after medication,
adding that mavrilimumab was well tolerated
    ** Says mavrilimumab recipients experienced a 65% reduction
in the risk of mechanical ventilation or death and a 61%
reduction in risk of death vs placebo 
    ** Enrollment in next portion of trial ongoing and co
expects to provide next steps for broader development program of
the drug this quarter  - KNSA
    ** Shares are up marginally this year
    

 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com;))